Biotechnology, Pharmaceutical and Life Science Reports and Courses

Main Pages

Best Selling Products

BioNewsCast Press Release Distribution Service

3rd Annual Stability Testing Conference

Next-Gen Sequencing Trends 2009

Competitor Analysis: c-MET/HGF Inhibitors

The Japanese Pharmaceutical Market 2008-2023

New Products

Japanese Pharmaceutical Market 2009-2024

3rd Annual Lyophilisation Conference

The Global Bioinformatics Market: Market size, forecasts and company profiles

Pharmaceutical Mergers and Acquisitions (PH133)

Pharmaceutical Speaker Programs (PH134) Measuring ROI and Communicating Value

Strategic Clinical Sourcing (PH125)) Managing Costs and CROs

The Global Analgesics Market 2009-2024

Competitor Analysis: Coagulation Factors

Competitor Analysis: PDGF-R Agonists and Antagonists

World Market for Addiction Disorders, 2009-2016

BioPortfolio | Donald Macarthur | Pharmaceutical Pricing and Distribution in Japan: The keys to success in the world’s second largest market

Pharmaceutical Pricing and Distribution in Japan: The keys to success in the world’s second largest market

No serious multinational can afford to ignore Japan, but it remains a tough and highly competitive market to crack, with the environment for developing and marketing medicines dominated by price. Virtually no new prescription brand can be introduced without a yakka (reimbursement price) set by the government. Innovative new drugs receive price premiums while others are capped at the price of older entrants. Discounting to the trade is inescapable, but is punished by downward price revisions on a scale and frequency unseen elsewhere. Big selling brands and now others in the same class are subject to special price cuts. Distribution is inherently linked to the pricing process and is particularly opaque to outsiders.

Whether the challenge is entering the Japanese market for the first time, moving up the all important ranking there by market share, or negotiating with a local in licensing partner, this report is designed to help.

· New drug pricing and price revision processes explained

· Written by an acknowledged expert on the Japanese market with 20 years' experience

· Fully researched through field interviews conducted in Tokyo and Osaka with industry leaders, government officials and others during March 2008

· Incorporates all pricing rule changes that came into effect from April 2008

· Progeneric measures critically appraised

· Key role of wholesalers and how they are paid clarified

· Prospects for future reform to the P&R processes discussed

Author: Donald Macarthur

First published: June 2008

Length: Approx 110 pages

Format: PDF
Table of Contents
Price: $2,295.00 / €1,535.36

BioPortfolio uses RBS Worldpay Secure Server for credit card transactions